Abstract
Esophageal cancer commonly has a poor prognosis, which requires an accurate diagnosis and early treatment to improve outcome. Other modalities for staging, such as endoscopic ultrasound imaging and computed tomography (CT) scans, have a role in diagnosis and staging. However, PET with fluorine-18 fluoro-2-deoxy-D-glucose/CT (FDG PET/CT) scanning allows for improved detection of distant metastatic disease and can help to prevent unnecessary interventions that would increase morbidity. FDG PET/CT scanning is valuable in the neoadjuvant chemotherapy assessment and predicting survival outcomes subsequent to surgery. FDG PET/CT scanning detects recurrent disease and metastases in follow-up.
Original language | English (US) |
---|---|
Pages (from-to) | 373-391 |
Number of pages | 19 |
Journal | PET Clinics |
Volume | 12 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2017 |
Keywords
- Esophageal cancer
- Esophageal carcinoma
- FDG PET/CT
- PET
- PET/CT
ASJC Scopus subject areas
- Radiation
- Radiology Nuclear Medicine and imaging